Semaglutide Side Effects: What the Research Shows

Common side effects

Semaglutide slows how quickly the stomach empties and affects appetite signalling, which explains why digestive symptoms dominate the side-effect profile reported across clinical trials of the molecule. Most people experience these effects, if at all, as mild to moderate and temporary.

• Nausea, the most frequently reported effect, particularly after starting or increasing a dose
• Diarrhea or constipation
• Vomiting
• Reduced appetite and earlier fullness during meals

These effects are the reason semaglutide is titrated gradually rather than started at a full dose. Slower titration schedules are associated with better tolerability in the clinical literature.

Side effects by frequency

The table below groups the side effects most often discussed in semaglutide product information and trial data by how frequently they are reported. It is a general reference, not a prediction of what any one person will experience.

Serious risks

Beyond the common digestive effects, regulatory safety reviews and product information for semaglutide describe a small number of more serious risks. They are uncommon, but a licensed clinician screens for relevant history before prescribing and explains what to watch for.

• Pancreatitis, which can present as severe, persistent abdominal pain, sometimes with vomiting
• Gallbladder problems, including gallstones, which can cause upper abdominal pain
• Increased heart rate, which some people notice and which your clinician can monitor
• A possible link to worsening diabetic retinopathy in people who already have diabetic eye disease and experience rapid improvement in blood sugar control
• A labelled caution regarding thyroid C-cell tumors, based on findings in animal studies, which is why a personal or family history of certain thyroid cancers is screened for before prescribing

Because semaglutide can affect blood sugar, combining it with insulin or other glucose-lowering medications raises the risk of hypoglycemia. Your prescriber reviews your full medication list before starting treatment and adjusts other medications if needed.

Monitoring and follow-up

Ongoing semaglutide care generally includes periodic follow-up so your prescriber can check how you are tolerating the medication, review whether the dose should change, and confirm that any relevant health measures are moving in the expected direction. The exact monitoring schedule depends on why you were prescribed semaglutide and your individual health history, and it is set by your clinician rather than by any general guide.

Tell your prescriber about any new symptom, not just the ones on a checklist. Side effects can present differently from person to person, and early reporting makes it easier to manage them.

Providers who manage your care

A licensed Canadian telehealth provider reviews your medical history during an online assessment, decides independently whether semaglutide is appropriate, and remains available for follow-up as you titrate. The providers below publish their own program details.

When to seek care

Contact your prescriber if side effects are severe, do not improve, or make it difficult to eat or stay hydrated. Seek urgent medical attention for severe or persistent abdominal pain, ongoing vomiting, signs of a serious allergic reaction, or any symptom that concerns you. Do not change your dose on your own; any adjustment should go through your prescribing clinician.

Frequently asked questions

What are the most common side effects of semaglutide?

Across clinical trials, the effects reported most often are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are typically mild to moderate in severity and most common during dose increases, easing as the body adjusts to a given dose.

Do side effects differ between the injectable and oral forms of semaglutide?

The general side-effect profile is similar because the active ingredient is the same, but the oral tablet form is taken with specific administration instructions, such as taking it on an empty stomach, that can affect how it is tolerated. Discuss the differences with your prescriber if you are choosing between forms.

What serious risks are associated with semaglutide?

Serious but uncommon risks reported in the clinical literature include pancreatitis, gallbladder problems such as gallstones, and, in rare cases, worsening of diabetic retinopathy in people with existing diabetic eye disease. A clinician reviews your medical history before prescribing to weigh these risks for you specifically.

How is semaglutide use monitored over time?

Ongoing care with semaglutide typically includes periodic check-ins with your prescriber, monitoring of how you are tolerating the medication, and review of relevant health measures depending on why it was prescribed. Your specific monitoring plan is set by your clinician, not by this article.

Can semaglutide cause low blood sugar?

On its own, semaglutide carries a low risk of hypoglycemia. The risk rises when it is combined with other diabetes medications that lower blood sugar, such as insulin or sulfonylureas. Your prescriber accounts for your full medication list when planning treatment.

Who should discuss additional caution with a clinician before starting semaglutide?

People with a personal or family history of certain thyroid tumors, a history of pancreatitis, significant gastrointestinal disease, or who are pregnant or planning pregnancy should raise this directly with a licensed clinician, who will decide whether semaglutide is appropriate.

Is semaglutide safe for long-term use?

Large trials such as SUSTAIN-6 and SELECT followed patients over multiple years and reported on both efficacy and safety outcomes. Long-term suitability for any individual is a clinical decision made with your prescriber based on your health history and how you respond to treatment.

Sources and related reading

This guide references Health Canada safety review documentation for GLP-1 receptor agonists, NCBI clinical reference material, and landmark clinical trials of semaglutide. It is educational and does not replace advice from your prescribing clinician.